首页 > 最新文献

Bipolar Disorders最新文献

英文 中文
Hospital-treated bipolar disorder in adolescence in Finland 1980-2010: Rehospitalizations, diagnostic stability, and mortality. 1980-2010年在芬兰接受医院治疗的青少年躁郁症患者:再住院、诊断稳定性和死亡率。
IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-12 DOI: 10.1111/bdi.13486
Anna Repo, Riittakerttu Kaltiala, Timo Holttinen

Aims: Estimates of the occurrence of bipolar disorder among adolescents vary from country to country and from time to time. Long delays from first symptoms to diagnosis of bipolar disorder have been suggested. Studies among adults suggest increased mortality, particularly due to suicide and cardiovascular diseases. We set out to study the prognosis of adolescent onset bipolar disorder in terms of rehospitalizations, diagnostic stability, and mortality.

Methods: The study comprised a register-based follow-up of all adolescents admitted to psychiatric inpatient care for the first time in their lives at age 13-17 during the period 1980-2010. They were followed up in the National Care Register for Health Care and Causes of death registers until 31 December 2014.

Results: Incidence of bipolar disorder among 13- to 17-year-old adolescents over the whole study period was 2.8 per 100, 000 same aged adolescents, and across decades, the incidence increased six-fold. Patients with bipolar disorder during their first-ever inpatient treatment were rehospitalized more often than those treated for other reasons. Conversion from bipolar disorder to other diagnoses was far more common than the opposite. Mortality did not differ between those firstdiagnosed with bipolar disorder and those treated for other reasons.

Conclusion: The incidence of adolescent onset bipolar disorder has increased across decades. The present study does not call for attention to delayed diagnosis of bipolar disorder. Adolescent onset bipolar disorders are severe disorders that often require rehospitalization, but diagnostic stability is modest. Mortality is comparable to that in other equally serious disorders.

目的:不同国家和不同时期对青少年躁郁症发病率的估计各不相同。有研究表明,从首次出现症状到确诊为躁狂症需要很长时间。对成年人的研究表明,躁郁症会增加死亡率,尤其是自杀和心血管疾病。我们试图从再住院、诊断稳定性和死亡率等方面研究青少年躁郁症的预后:研究包括对1980-2010年间所有13-17岁首次入住精神病院的青少年进行登记跟踪。他们在全国医疗保健登记册和死亡原因登记册中接受了跟踪调查,直至2014年12月31日:结果:在整个研究期间,13至17岁青少年的躁郁症发病率为每10万名同龄青少年中有2.8人罹患躁郁症。与那些因其他原因接受治疗的患者相比,首次接受住院治疗的躁郁症患者再次住院的频率更高。从双相情感障碍转为其他诊断的情况要比相反的情况常见得多。首次被诊断为躁狂症的患者与因其他原因接受治疗的患者的死亡率没有差异:结论:几十年来,青少年躁郁症的发病率一直在上升。结论:几十年来,青少年躁郁症的发病率一直在上升,但本研究并未呼吁人们关注躁郁症的延迟诊断。青少年双相情感障碍是一种严重的疾病,常常需要再次住院治疗,但诊断的稳定性并不高。死亡率与其他同样严重的疾病相当。
{"title":"Hospital-treated bipolar disorder in adolescence in Finland 1980-2010: Rehospitalizations, diagnostic stability, and mortality.","authors":"Anna Repo, Riittakerttu Kaltiala, Timo Holttinen","doi":"10.1111/bdi.13486","DOIUrl":"10.1111/bdi.13486","url":null,"abstract":"<p><strong>Aims: </strong>Estimates of the occurrence of bipolar disorder among adolescents vary from country to country and from time to time. Long delays from first symptoms to diagnosis of bipolar disorder have been suggested. Studies among adults suggest increased mortality, particularly due to suicide and cardiovascular diseases. We set out to study the prognosis of adolescent onset bipolar disorder in terms of rehospitalizations, diagnostic stability, and mortality.</p><p><strong>Methods: </strong>The study comprised a register-based follow-up of all adolescents admitted to psychiatric inpatient care for the first time in their lives at age 13-17 during the period 1980-2010. They were followed up in the National Care Register for Health Care and Causes of death registers until 31 December 2014.</p><p><strong>Results: </strong>Incidence of bipolar disorder among 13- to 17-year-old adolescents over the whole study period was 2.8 per 100, 000 same aged adolescents, and across decades, the incidence increased six-fold. Patients with bipolar disorder during their first-ever inpatient treatment were rehospitalized more often than those treated for other reasons. Conversion from bipolar disorder to other diagnoses was far more common than the opposite. Mortality did not differ between those firstdiagnosed with bipolar disorder and those treated for other reasons.</p><p><strong>Conclusion: </strong>The incidence of adolescent onset bipolar disorder has increased across decades. The present study does not call for attention to delayed diagnosis of bipolar disorder. Adolescent onset bipolar disorders are severe disorders that often require rehospitalization, but diagnostic stability is modest. Mortality is comparable to that in other equally serious disorders.</p>","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":" ","pages":"793-800"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11627002/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970582","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Concept article: Antidepressant-induced destabilization in bipolar illness mediated by serotonin 3 receptor (5HT3). 概念文章:血清素 3 受体(5HT3)介导的抗抑郁药诱导的双相情感障碍疾病的不稳定性。
IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-09-01 DOI: 10.1111/bdi.13494
Irem Hacisalihoglu Aydin, Rif S El-Mallakh

Objectives: Antidepressants used by patients with bipolar disorder have been associated with destabilization with an increase in mania, depression, and cycling. The most commonly proposed mechanism, that antidepressants 'overshoot' their antidepressant effect to create a manic or mixed state, is unlikely since antidepressants have actually been found to be ineffective in treating bipolar depression. Beginning with known bipolar-specific pathophysiologic abnormalities provides the greatest likelihood of insight.

Methods: PubMed was queried with 'bipolar', 'sodium', 'intracellular sodium', 'serotonin 3', '5HT3', '5-hydroxytryptamine type 3 receptors', and 'antidepressant' either individually or in combination.

Results: Pathologic mood states (both mania and depression) are associated with increased intracellular sodium (Na) concentrations that depolarize the resting membrane potential to increase cellular excitability (mania) or cause depolarization block (depression). Stimulation of the serotonin (5HT) receptors depolarizes the post-synaptic neuron. Stimulation of 5HT3 may be of particular importance since it is coupled to a cation channel that directly depolarizes the membrane. These effects directly impact the physiology of patients with bipolar disorder to alter neuronal excitability in a fashion that worsens both mania and depression.

Proposed concept: The most consistently observed biological abnormality in individuals going through mania or bipolar depression involves a decline in Na pump activity, with consequent elevation of intracellular Na levels. Antidepressant treatment potentiates this, particularly by activation of 5HT3. This hypothesis can be tested by coadministering a 5HT3 antagonist (e.g., vortioxetine or ondansetron) to achieve blockade of that receptor while treating bipolar depression with a serotoninergic antidepressant.

目的:双相情感障碍患者使用抗抑郁药与躁狂、抑郁和周期性增加的不稳定状态有关。最常见的机制是抗抑郁药的抗抑郁效果 "超标",从而导致躁狂或混合状态,但这种机制并不可行,因为抗抑郁药实际上对治疗双相抑郁症无效。从已知的双相特异性病理生理异常入手,最有可能获得深刻的见解:方法:在 PubMed 上以 "双相"、"钠"、"细胞内钠"、"5-羟色胺 3"、"5HT3"、"5-羟色胺 3 型受体 "和 "抗抑郁剂 "为关键词进行单独或组合检索:病理性情绪状态(包括躁狂症和抑郁症)与细胞内钠(Na)浓度增加有关,钠(Na)浓度增加会使静息膜电位去极化,从而增加细胞兴奋性(躁狂症)或导致去极化阻滞(抑郁症)。刺激血清素(5HT)受体可使突触后神经元去极化。对 5HT3 的刺激可能尤为重要,因为它与直接使膜去极化的阳离子通道相耦合。这些效应直接影响躁郁症患者的生理机能,改变神经元的兴奋性,从而使躁狂症和抑郁症恶化:躁狂症或双相抑郁症患者最常出现的生物异常是 Na 泵活性下降,从而导致细胞内 Na 水平升高。抗抑郁剂治疗会增强这种作用,尤其是通过激活 5HT3 的作用。这一假设可以通过联合使用 5HT3 拮抗剂(如伏替西汀或昂丹司琼)来验证,从而在使用血清素能抗抑郁剂治疗双相抑郁的同时阻断该受体。
{"title":"Concept article: Antidepressant-induced destabilization in bipolar illness mediated by serotonin 3 receptor (5HT3).","authors":"Irem Hacisalihoglu Aydin, Rif S El-Mallakh","doi":"10.1111/bdi.13494","DOIUrl":"10.1111/bdi.13494","url":null,"abstract":"<p><strong>Objectives: </strong>Antidepressants used by patients with bipolar disorder have been associated with destabilization with an increase in mania, depression, and cycling. The most commonly proposed mechanism, that antidepressants 'overshoot' their antidepressant effect to create a manic or mixed state, is unlikely since antidepressants have actually been found to be ineffective in treating bipolar depression. Beginning with known bipolar-specific pathophysiologic abnormalities provides the greatest likelihood of insight.</p><p><strong>Methods: </strong>PubMed was queried with 'bipolar', 'sodium', 'intracellular sodium', 'serotonin 3', '5HT<sub>3</sub>', '5-hydroxytryptamine type 3 receptors', and 'antidepressant' either individually or in combination.</p><p><strong>Results: </strong>Pathologic mood states (both mania and depression) are associated with increased intracellular sodium (Na) concentrations that depolarize the resting membrane potential to increase cellular excitability (mania) or cause depolarization block (depression). Stimulation of the serotonin (5HT) receptors depolarizes the post-synaptic neuron. Stimulation of 5HT<sub>3</sub> may be of particular importance since it is coupled to a cation channel that directly depolarizes the membrane. These effects directly impact the physiology of patients with bipolar disorder to alter neuronal excitability in a fashion that worsens both mania and depression.</p><p><strong>Proposed concept: </strong>The most consistently observed biological abnormality in individuals going through mania or bipolar depression involves a decline in Na pump activity, with consequent elevation of intracellular Na levels. Antidepressant treatment potentiates this, particularly by activation of 5HT<sub>3</sub>. This hypothesis can be tested by coadministering a 5HT<sub>3</sub> antagonist (e.g., vortioxetine or ondansetron) to achieve blockade of that receptor while treating bipolar depression with a serotoninergic antidepressant.</p>","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":" ","pages":"772-778"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142103932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Recent trends in hospital admission due to bipolar disorder in 10-19-year-olds in Spain: A nationwide population-based study. 西班牙 10-19 岁儿童因躁郁症入院的最新趋势:一项基于全国人口的研究。
IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-09-05 DOI: 10.1111/bdi.13500
Teresa López-Cuadrado, Ezra Susser, Gonzalo Martínez-Alés

Introduction: Bipolar disorder (BD) hospitalization rates in children and adolescents vary greatly across place and over time. There are no population-based studies on youth BD hospitalizations in Spain.

Methods: We identified all patients aged 10-19 hospitalized due to BD in Spain between 2000 and 2021, examined their demographic and clinical characteristics, and assessed temporal trends in hospitalizations - overall and stratified by age and presence of additional psychiatric comorbidity. We used Joinpoint regressions to identify inflection points and quantify whole-period and annual percentage changes (APCs) in trends.

Results: Of 4770 BD hospitalizations in 10-19-year-olds between 2000 and 2021 (average annual rate: 4.8 per 100,000), over half indicated an additional psychiatric comorbidity, most frequently substance abuse (62.2%), mostly due to cannabis (72.4%). During the study period, admissions increased twofold with an inflection point: Rates increased annually only between 2000 and 2008, for APCs 34.0% (95% confidence interval: 20.0%, 71.1%) among 10-14-year-olds, 10.3% (6.4%, 14.3%) among 15-19-year-olds, and 15.5% (11.5%, 22.7%) among patients with additional psychiatric comorbidity. Between 2009 and 2021, rates decreased moderately among 10-14-year-olds - APC: -8.3% (-14.1%, -4.4%) and slightly among 15-19-year-olds without additional psychiatric comorbidity - APC: -2.6(-5.7, -1.0), remaining largely stable among 15-19-year-olds overall.

Conclusions: Recent trends in hospitalization due to BD in 10-19-year-olds in Spain indicate salient increases in the early 2000s - especially among (i) patients aged 10-14 (decreasing moderately after 2009 among 10-14-year-olds and plateauing among 15-19-year-olds) and (ii) patients with additional psychiatric comorbidity (i.e., cannabis use disorder). These findings suggest links with recent changes in clinical practices for children and recent trends in substance use among Spanish youth.

导言:躁郁症(BD)在儿童和青少年中的住院率因地区和时间的不同而有很大差异。目前还没有关于西班牙青少年躁郁症住院率的人群研究:我们确定了 2000 年至 2021 年期间西班牙所有因躁狂症住院的 10-19 岁患者,研究了他们的人口统计学和临床特征,并评估了住院治疗的时间趋势--总体趋势以及根据年龄和是否存在其他精神疾病合并症进行的分层趋势。我们使用联结点回归来确定拐点,并量化趋势的全周期和年度百分比变化(APCs):2000 年至 2021 年间,在 4770 例 10-19 岁的 BD 住院病例中(年平均发病率:每 10 万人中有 4.8 例),超过一半的病例显示有额外的精神疾病合并症,其中最常见的是药物滥用(62.2%),大部分是由于大麻(72.4%)。在研究期间,入院人数增加了两倍,并出现了一个拐点:仅在 2000 年至 2008 年期间,入院率逐年上升,10-14 岁儿童的入院率为 34.0%(95% 置信区间:20.0%, 71.1%),15-19 岁儿童的入院率为 10.3%(6.4%, 14.3%),合并其他精神疾病的患者的入院率为 15.5%(11.5%, 22.7%)。2009年至2021年期间,10-14岁人群的发病率略有下降--APC:-8.3%(-14.1%,-4.4%),15-19岁无其他精神疾病合并症的人群的发病率略有下降--APC:-2.6(-5.7,-1.0),15-19岁人群的发病率总体上基本保持稳定:西班牙 10-19 岁儿童因 BD 住院治疗的最新趋势表明,2000 年代初,BD 住院治疗人数明显增加,尤其是在以下人群中:(i) 10-14 岁的患者(2009 年后,10-14 岁的患者人数适度减少,15-19 岁的患者人数趋于平稳);(ii) 有其他精神疾病合并症(即大麻使用障碍)的患者。这些研究结果表明,儿童临床实践的最新变化与西班牙青少年使用药物的最新趋势有关。
{"title":"Recent trends in hospital admission due to bipolar disorder in 10-19-year-olds in Spain: A nationwide population-based study.","authors":"Teresa López-Cuadrado, Ezra Susser, Gonzalo Martínez-Alés","doi":"10.1111/bdi.13500","DOIUrl":"10.1111/bdi.13500","url":null,"abstract":"<p><strong>Introduction: </strong>Bipolar disorder (BD) hospitalization rates in children and adolescents vary greatly across place and over time. There are no population-based studies on youth BD hospitalizations in Spain.</p><p><strong>Methods: </strong>We identified all patients aged 10-19 hospitalized due to BD in Spain between 2000 and 2021, examined their demographic and clinical characteristics, and assessed temporal trends in hospitalizations - overall and stratified by age and presence of additional psychiatric comorbidity. We used Joinpoint regressions to identify inflection points and quantify whole-period and annual percentage changes (APCs) in trends.</p><p><strong>Results: </strong>Of 4770 BD hospitalizations in 10-19-year-olds between 2000 and 2021 (average annual rate: 4.8 per 100,000), over half indicated an additional psychiatric comorbidity, most frequently substance abuse (62.2%), mostly due to cannabis (72.4%). During the study period, admissions increased twofold with an inflection point: Rates increased annually only between 2000 and 2008, for APCs 34.0% (95% confidence interval: 20.0%, 71.1%) among 10-14-year-olds, 10.3% (6.4%, 14.3%) among 15-19-year-olds, and 15.5% (11.5%, 22.7%) among patients with additional psychiatric comorbidity. Between 2009 and 2021, rates decreased moderately among 10-14-year-olds - APC: -8.3% (-14.1%, -4.4%) and slightly among 15-19-year-olds without additional psychiatric comorbidity - APC: -2.6(-5.7, -1.0), remaining largely stable among 15-19-year-olds overall.</p><p><strong>Conclusions: </strong>Recent trends in hospitalization due to BD in 10-19-year-olds in Spain indicate salient increases in the early 2000s - especially among (i) patients aged 10-14 (decreasing moderately after 2009 among 10-14-year-olds and plateauing among 15-19-year-olds) and (ii) patients with additional psychiatric comorbidity (i.e., cannabis use disorder). These findings suggest links with recent changes in clinical practices for children and recent trends in substance use among Spanish youth.</p>","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":" ","pages":"801-809"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142139223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Does serotonin reuptake inhibition provoke catatonia in patients with bipolar illness? 血清素再摄取抑制会引发双相情感障碍患者的紧张症吗?
IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-05-14 DOI: 10.1111/bdi.13458
Nicholas Bonomo, Irem Hacisalihoglu Aydin, Rif S El-Mallakh
{"title":"Does serotonin reuptake inhibition provoke catatonia in patients with bipolar illness?","authors":"Nicholas Bonomo, Irem Hacisalihoglu Aydin, Rif S El-Mallakh","doi":"10.1111/bdi.13458","DOIUrl":"10.1111/bdi.13458","url":null,"abstract":"","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":" ","pages":"827-830"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140921233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Should we combine antipsychotics in patients with bipolar disorder? 双相情感障碍患者是否应该联合使用抗精神病药物?
IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-07-29 DOI: 10.1111/bdi.13482
Vanessa Gnielka, Thiago Henrique Roza, Ives Cavalcante Passos
{"title":"Should we combine antipsychotics in patients with bipolar disorder?","authors":"Vanessa Gnielka, Thiago Henrique Roza, Ives Cavalcante Passos","doi":"10.1111/bdi.13482","DOIUrl":"10.1111/bdi.13482","url":null,"abstract":"","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":" ","pages":"761-763"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141791828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical and sociodemographic characteristics associated with relapse following electroconvulsive therapy for bipolar disorder. 与双相情感障碍电休克疗法后复发相关的临床和社会人口特征。
IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-12 DOI: 10.1111/bdi.13485
Rasmus Bengt Thomsen, Estela Salagre, Christopher Rohde, Søren Dinesen Østergaard

Objectives: Electroconvulsive therapy (ECT) is an effective treatment for bipolar disorder, but relapse following a successful ECT series is common. We aimed to identify clinical and sociodemographic characteristics associated with the risk of relapse following ECT in bipolar disorder.

Methods: Using data from nationwide Danish registers, we identified all patients receiving their first ECT series with an indication diagnosis of bipolar disorder between 2006 and 2018. We then followed these patients for relapse, defined as either psychiatric admission or a new ECT series, for 6 months following ECT. Associations between clinical and sociodemographic characteristics and relapse were examined via multivariable Cox proportional-hazards regression, yielding adjusted hazard rate ratios (aHRR).

Results: Of the 1473 patients receiving ECT for bipolar disorder (62% females, mean age = 53 years), 34% met the relapse criterion. The following characteristics were associated with an elevated risk of relapse; age <40 (aHRR = 1.54, 95% CI = 1.05-2.26); being a pensioner (aHRR = 1.73, 95% CI = 1.29-2.32), indication diagnosis for ECT being psychotic mania (aHRR = 1.63, 95% CI = 1.16-2.28), psychotic bipolar depression (aHRR = 1.37, 95% CI = 1.06-1.80), mixed episode (aHRR = 1.51, 95% CI = 1.13-2.02), or other bipolar episodes (aHRR = 1.68, 95% CI = 1.28-2.21); and treatment with antipsychotics prior to the course of ECT (aHRR = 1.32, 95% CI = 1.04-1.67).

Conclusion: Patients with bipolar disorder face a particularly high risk of relapse following ECT if they present with the following characteristics when initiating ECT: age <40, being a pensioner, having received treatment with an antipsychotic before initiating ECT, or having psychotic bipolar depression, psychotic mania, mixed episodes, or other bipolar episodes as the indication for ECT. These findings may guide relapse monitoring following ECT in bipolar disorder.

目的:电休克疗法(ECT)是治疗躁郁症的一种有效方法,但在一系列成功的ECT治疗后复发的情况很常见。我们旨在确定与双相情感障碍电休克疗法后复发风险相关的临床和社会人口特征:我们利用丹麦全国性登记册中的数据,确定了 2006 年至 2018 年间接受首次电痉挛疗法治疗的所有患者,其适应症诊断为双相情感障碍。然后,我们对这些患者的复发情况进行了跟踪调查,复发的定义是在接受电痉挛疗法后的 6 个月内入院治疗或再次接受电痉挛疗法。我们通过多变量考克斯比例危害回归检验了临床和社会人口学特征与复发之间的关系,得出了调整后的危害率比(aHRR):在接受电痉挛疗法治疗双相情感障碍的 1473 名患者中(62% 为女性,平均年龄为 53 岁),34% 符合复发标准。以下特征与复发风险升高有关:年龄 结论:双相情感障碍患者面临着复发的风险:如果双相情感障碍患者在开始接受电痉挛疗法时具有以下特征,那么他们在接受电痉挛疗法后复发的风险会特别高:年龄
{"title":"Clinical and sociodemographic characteristics associated with relapse following electroconvulsive therapy for bipolar disorder.","authors":"Rasmus Bengt Thomsen, Estela Salagre, Christopher Rohde, Søren Dinesen Østergaard","doi":"10.1111/bdi.13485","DOIUrl":"10.1111/bdi.13485","url":null,"abstract":"<p><strong>Objectives: </strong>Electroconvulsive therapy (ECT) is an effective treatment for bipolar disorder, but relapse following a successful ECT series is common. We aimed to identify clinical and sociodemographic characteristics associated with the risk of relapse following ECT in bipolar disorder.</p><p><strong>Methods: </strong>Using data from nationwide Danish registers, we identified all patients receiving their first ECT series with an indication diagnosis of bipolar disorder between 2006 and 2018. We then followed these patients for relapse, defined as either psychiatric admission or a new ECT series, for 6 months following ECT. Associations between clinical and sociodemographic characteristics and relapse were examined via multivariable Cox proportional-hazards regression, yielding adjusted hazard rate ratios (aHRR).</p><p><strong>Results: </strong>Of the 1473 patients receiving ECT for bipolar disorder (62% females, mean age = 53 years), 34% met the relapse criterion. The following characteristics were associated with an elevated risk of relapse; age <40 (aHRR = 1.54, 95% CI = 1.05-2.26); being a pensioner (aHRR = 1.73, 95% CI = 1.29-2.32), indication diagnosis for ECT being psychotic mania (aHRR = 1.63, 95% CI = 1.16-2.28), psychotic bipolar depression (aHRR = 1.37, 95% CI = 1.06-1.80), mixed episode (aHRR = 1.51, 95% CI = 1.13-2.02), or other bipolar episodes (aHRR = 1.68, 95% CI = 1.28-2.21); and treatment with antipsychotics prior to the course of ECT (aHRR = 1.32, 95% CI = 1.04-1.67).</p><p><strong>Conclusion: </strong>Patients with bipolar disorder face a particularly high risk of relapse following ECT if they present with the following characteristics when initiating ECT: age <40, being a pensioner, having received treatment with an antipsychotic before initiating ECT, or having psychotic bipolar depression, psychotic mania, mixed episodes, or other bipolar episodes as the indication for ECT. These findings may guide relapse monitoring following ECT in bipolar disorder.</p>","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":" ","pages":"785-792"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11627001/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141970580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Progesterone for premenstrual exacerbations of bipolar disorder in a 15-year-old girl with polycystic ovary syndrome. 黄体酮治疗一名患有多囊卵巢综合征的 15 岁女孩的经前躁狂症。
IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-05-16 DOI: 10.1111/bdi.13457
Haixin Cen, Liuqing Zhang, Fengju Liu
{"title":"Progesterone for premenstrual exacerbations of bipolar disorder in a 15-year-old girl with polycystic ovary syndrome.","authors":"Haixin Cen, Liuqing Zhang, Fengju Liu","doi":"10.1111/bdi.13457","DOIUrl":"10.1111/bdi.13457","url":null,"abstract":"","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":" ","pages":"824-826"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140955921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Menopause and bipolar disorder: Bridging research gaps and exploring postmenopause. 更年期与躁郁症:缩小研究差距,探索绝经后。
IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-08-04 DOI: 10.1111/bdi.13483
Francesco Attanasio, Valentina Fazio, Carlotta Pira, Elena Manfredi, Lorenzo Fregna, Cristina Colombo
{"title":"Menopause and bipolar disorder: Bridging research gaps and exploring postmenopause.","authors":"Francesco Attanasio, Valentina Fazio, Carlotta Pira, Elena Manfredi, Lorenzo Fregna, Cristina Colombo","doi":"10.1111/bdi.13483","DOIUrl":"10.1111/bdi.13483","url":null,"abstract":"","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":" ","pages":"821-822"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626994/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141888455","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to "Supercharging collaboration for bipolar research-Breakthrough discoveries for thriving with bipolar disorder (BD2)". 双相情感障碍研究的超级合作--为双相情感障碍患者的茁壮成长带来突破性发现(BD2)"的更正。
IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-01-29 DOI: 10.1111/bdi.13407
{"title":"Correction to \"Supercharging collaboration for bipolar research-Breakthrough discoveries for thriving with bipolar disorder (BD<sup>2</sup>)\".","authors":"","doi":"10.1111/bdi.13407","DOIUrl":"10.1111/bdi.13407","url":null,"abstract":"","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":" ","pages":"823"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139575254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ketamine and lamotrigine combination in mood disorders-A call for real-world evidence reporting. 氯胺酮和拉莫三嗪联合治疗情绪障碍--呼吁报告真实世界的证据。
IF 5 2区 医学 Q1 CLINICAL NEUROLOGY Pub Date : 2024-12-01 Epub Date: 2024-07-28 DOI: 10.1111/bdi.13478
Alina Wilkowska, Mariusz S Wiglusz, Wiesław J Cubała
{"title":"Ketamine and lamotrigine combination in mood disorders-A call for real-world evidence reporting.","authors":"Alina Wilkowska, Mariusz S Wiglusz, Wiesław J Cubała","doi":"10.1111/bdi.13478","DOIUrl":"10.1111/bdi.13478","url":null,"abstract":"","PeriodicalId":8959,"journal":{"name":"Bipolar Disorders","volume":" ","pages":"820"},"PeriodicalIF":5.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787243","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Bipolar Disorders
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1